P/E společnosti Beam Therapeutics

Jaká je hodnota metriky P/E společnosti Beam Therapeutics?

Hodnota metriky P/E společnosti Beam Therapeutics Inc. je N/A

Jaká je definice metriky P/E?

P/E ratio je koeficient daný poměrem ceny akcie a příjmu společnosti na akcii za posledních 12 měsíců.

The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.

Čemu se věnuje společnost Beam Therapeutics?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Firmy s metrikou p/e podobnou společnosti Beam Therapeutics

Hodnota metriky P/E společnosti Glittek Granites je N/A
Hodnota metriky P/E společnosti Nanalysis Scientific je N/A
Hodnota metriky P/E společnosti Shuanghua je N/A
Hodnota metriky P/E společnosti Blue Rhino Capital je N/A
Hodnota metriky P/E společnosti Angus Ventures Inc je N/A
Hodnota metriky P/E společnosti Dynamo Capital je N/A
Hodnota metriky P/E společnosti Beam Therapeutics je N/A
Hodnota metriky P/E společnosti China Singyes New Materials je N/A
Hodnota metriky P/E společnosti Fusion Gold je N/A
Hodnota metriky P/E společnosti DigitalX je N/A
Hodnota metriky P/E společnosti Genfit SA je N/A
Hodnota metriky P/E společnosti Deltic Plc je N/A
Hodnota metriky P/E společnosti Zephyr Minerals je N/A